Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIIOngoingNov 5, 2025Everolimus tablets 5mgFailed Impurities/Degradation Specifications: Out of specification for impurity IP-C.Endo USA, Inc. · D-0139-2026Class IIIOngoingNov 5, 2025Espumil, Lipophilic foam baseLabeling: Not Elsewhere ClassifiedLetco Medical LLC · D-0138-2026Class IIOngoingNov 5, 2025Testosterone / Triamcinolone Acetonide PelletCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0137-2026Class IIOngoingNov 5, 2025Testosterone / Triamcinolone Acetonide PelletCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0136-2026Class IIOngoingNov 5, 2025Testosterone / Triamcinolone Acetonide 87.5MG/17.5MCGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0135-2026Class IIOngoingNov 5, 2025Testosterone / Triamcinolone AcetonideCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0134-2026Class IIOngoingNov 5, 2025Testosterone / Triamcinolone Acetonide 50MG/10MCGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0133-2026Class IIOngoingNov 5, 2025Testosterone / Triamcinolone Acetonide PelletCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0132-2026Class IIOngoingNov 5, 2025Testosterone / Triamcinolone Acetonide 25MG/5MCGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0131-2026Class IIOngoingNov 5, 2025Testosterone / Triamcinolone AcetonideCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0130-2026Class IIOngoingNov 5, 2025Testosterone Regular Release 200 MGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0129-2026Class IIOngoingNov 5, 2025Testosterone Regular Release 50 MGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0128-2026Class IIOngoingNov 5, 2025Testosterone 200 MGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0127-2026Class IIOngoingNov 5, 2025Testosterone 87.5 MGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0126-2026Class IIOngoingNov 5, 2025Testosterone 62.5 MGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0125-2026Class IIOngoingNov 5, 2025Testosterone 50MGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0124-2026Class IIOngoingNov 5, 2025Testosterone 25MGCGMP Deviations: Potential presence of metal particulate matterFarmakeio Outsourcing LLC · D-0123-2026Class IIOngoingNov 5, 2025Sting Relief SwabsProduct Mix-upAcme United Corporation · D-0122-2026Class IIOngoingNov 5, 2025TYLENOL, AcetaminophenDefective ContainerKenvue Brands LLC · D-0121-2026Class IIOngoingNov 5, 2025Tirzepatide InjectionLack of Assurance of SterilityProRx LLC · D-0120-2026Class IIOngoingNov 5, 2025Semaglutide InjectionLack of Assurance of SterilityProRx LLC · D-0119-2026Class IIOngoingNov 5, 2025Semaglutide InjectionLack of Assurance of SterilityProRx LLC · D-0118-2026Class IIOngoingNov 5, 2025Semaglutide InjectionLack of Assurance of SterilityProRx LLC · D-0117-2026Class IIOngoingNov 5, 2025Semaglutide InjectionLack of Assurance of SterilityProRx LLC · D-0116-2026Class IIOngoingNov 5, 2025Semaglutide InjectionLack of Assurance of SterilityProRx LLC · D-0115-2026Class IIOngoingNov 5, 2025Semaglutide InjectionLack of Assurance of SterilityProRx LLC · D-0114-2026Class IIOngoingNov 5, 2025R.E.C.KPresence of Particulate MatterQuVa Pharma, Inc. · D-0113-2026Class IIOngoingNov 5, 2025Desipramine Hydrochloride TabletsCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.Heritage Pharmaceuticals Inc · D-0112-2026Class IIOngoingNov 5, 2025Desipramine Hydrochloride TabletsCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.Heritage Pharmaceuticals Inc · D-0111-2026Class IIOngoingNov 5, 2025Desipramine Hydrochloride TabletsCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.Heritage Pharmaceuticals Inc · D-0110-2026Class IIOngoingNov 5, 2025Desipramine Hydrochloride TabletsCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.Heritage Pharmaceuticals Inc · D-0109-2026Class IIOngoingNov 5, 2025Desipramine Hydrochloride TabletsCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.Heritage Pharmaceuticals Inc · D-0108-2026Class IIOngoingNov 5, 2025Desipramine Hydrochloride TabletsCGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.Heritage Pharmaceuticals Inc · D-0107-2026Class IIOngoingNov 5, 2025Prazosin HydrochlorideCGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the...Teva Pharmaceuticals USA, Inc · D-0106-2026Class IIOngoingNov 5, 2025Prazosin HydrochlorideCGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the...Teva Pharmaceuticals USA, Inc · D-0105-2026Class IIOngoingNov 5, 2025Prazosin HydrochlorideCGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the...Teva Pharmaceuticals USA, Inc · D-0104-2026Class IIOngoingNov 5, 2025Prazosin HydrochlorideFailed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake...Amerisource Health Services LLC · D-0103-2026Class IIOngoingNov 5, 2025Prazosin HydrochlorideFailed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake...Amerisource Health Services LLC · D-0102-2026Class IIOngoingNov 5, 2025Prazosin HydrochlorideFailed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake...Amerisource Health Services LLC · D-0101-2026Class IIOngoingNov 5, 2025Duloxetine Delayed-Release CapsulesCGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.Breckenridge Pharmaceutical, Inc. · D-0100-2026